L-norleucine methyl ester | 21754-55-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-norleucine methyl ester
• 英文别名: methyl (2S)-2-aminohexanoate；norleucine methyl ester；O-Methyl-L-norleucine
• CAS: 21754-55-2
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: TVZNFYXAPXOARC-LURJTMIESA-N

物化性质

• 沸点：
  175.4±13.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-氨基己酸甲酯	methyl 2-aminohexanoate	51220-79-2	C7H15NO2	145.202
  L-正亮氨酸	L-Norleucine	327-57-1	C6H13NO2	131.175

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	methyl (S)-2-isocyanatohexanoate	96789-62-7	C8H13NO3	171.196

反应信息

• 作为反应物：
  描述：

  L-norleucine methyl ester 在 氨 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以85%的产率得到DL-norleucine amide
  参考文献：
  名称：

  Specificity of Lysine:N6-Hydroxylase: A Hypothesis for a Reactive Substrate Intermediate in the Catalytic Mechanism

  摘要：

  The recombinant cytoplasmic preparation of lysine: N-6-hydroxlase catalyzes the conversion of L-lysine to its N-6-hydroxy derivative when supplemented with the cofactors NADPH and FAD. A number of lysine analogs reflecting minor alterations in the inherent structural features of the amino acid as well compounds with relatively high affinity for lysine binding domains in other proteins were examined for their ability to serve as substrates of lysine: N-6-hydroxylase. These studies have revealed that the enzyme does not tolerate any change in the structural features of L-lysine, its preferred substrate, with the exception of the replacement of the CgammaH2-methylene group by sulfur, as in (S)-2-aminoethyl-L-cysteine. L-Norleucine is a potent inhibitor of the enzyme while L-norvaline and L-alpha-aminobutyric acid do not exhibit such effect, indicating the importance of a C-4 hydrophobic side chain for effective interaction with the enzyme. Among the N-alkyl amides of hydrophobic amino acids, only L-norleucine methylamide and L-alpha-aminobutyric acid ethylamide serve as moderate inhibitors of lysine : N-6-hydroxylase. Based on the enzyme's stringent substrate specificity, a mechanism involving the conversion of L-lysine to 2-aminocaprolactam prior to its oxygenation by the 4a-peroxyflavin intermediate in the catalytic cycle is proposed. (C) 1996 Academic Press, Inc.

  DOI：

  10.1006/bioo.1996.0034
• 作为产物：
  描述：

  甲醇 、 N-Boc-L-正亮氨酸 在 氯化亚砜 作用下， 反应 2.0h， 生成 L-norleucine methyl ester
  参考文献：
  名称：

  可溶性四肽环氧酮蛋白酶体抑制剂的制备和生物学评价。

  摘要：

  设计并合成了一系列新型的20S蛋白酶体四肽基环氧酮抑制剂。为了充分理解SAR，设计，合成和生物分析了R 1，R 2，R 3，R 4和R 5位置的各种基团，包括芳族和脂族取代基。基于酶促结果，选择了7种化合物来评估其细胞活性，可溶性化合物36对人多发性骨髓瘤（MM）细胞系显示出强大的功效。微粒体稳定性结果表明化合物36与市售的卡非佐米相比，它在小鼠，大鼠和人的微粒体中更稳定。用具有荧光素酶表达的MM细胞系ARH77和RPMI-8226的异种移植小鼠模型评价该化合物的体内活性，两个模型的T / C值分别为49.5％和37.6％。为了评估潜在的心血管毒性，化合物36和卡非佐米对HEK293细胞中的hERG离子通道进行了抑制。结果表明36对hERG离子通道没有结合亲和力，而卡非佐米可以与92.1μM的IC 50结合。

  DOI：

  10.1016/j.bmc.2019.07.044

文献信息

• Efficient synthesis of 2,5-diketopiperazines using microwave assisted heating
  作者：Marcus Tullberg、Morten Grøtli、Kristina Luthman

  DOI：10.1016/j.tet.2006.05.010

  日期：2006.7

  In this study a general, efficient and environmentally benign solution phase synthesis of 2,5-diketopiperazines (DKPs) using microwave assisted heating in water is described. A series of 11 structurally different DKPs have been synthesized from dipeptide methyl esters. A range of common laboratory solvents have been tested as well as different reaction times and temperatures. Both classic thermal and

  在这项研究中，描述了使用水中微波辅助加热的2，5-二酮哌嗪（DKP）的一般，有效和环境友好的溶液相合成方法。由二肽甲酯合成了一系列11种结构不同的DKP。已测试了一系列常见的实验室溶剂以及不同的反应时间和温度。经典的加热和微波辅助加热均已进行了研究。到目前为止，以水为溶剂的微波辅助加热10分钟被证明是最有效的环化方法，可产生中等至极佳的DKP收率（63-97％）。与其他已公开的程序相反，此方法似乎与氨基酸序列无关。
• Synthesis of Novel Chiral Phenanthroline Ligands and a Copper Complex
  作者：Xueyan Yang、Zhipeng Zhang、Jingjing Tang、Jian Li

  DOI：10.1055/a-1679-7161

  日期：2022.11

  A novel class of chiral multidentate ligands has been designed and synthesized from the important classic ligand 1,10-phenanthroline and amino acids. The ligands were proven to be able to coordinate with copper(2+) ion by the formation of a novel chiral copper complex, the structure of which was determined by single-crystal X-ray diffraction.

  从重要的经典配体 1,10-菲咯啉和氨基酸中设计并合成了一类新的手性多齿配体。通过形成新型手性铜配合物，证明配体能够与铜 (2+) 离子配位，其结构由单晶 X 射线衍射确定。
• Synthèse d'analogues structuraux de l'élédoïsine. 1^repartie: Préparation des produits intermédiaires
  作者：Ed. Sandrin、R. A. Boissonnas

  DOI：10.1002/hlca.19630460518

  日期：——

  The preparation of new dipeptides and tripeptides, which are useful intermediates in the synthesis of Eledoisin analogues, is described.

  描述了新的二肽和三肽的制备，它们是Eledoisin类似物合成中的有用中间体。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。